FDA Approves Tebipenem Pivoxil, First Oral Carbapenem for Complicated UTIs

The U.S. Food and Drug Administration (FDA) has approved tebipenem pivoxil (Utebzi) for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis. This marks the first oral carbapenem antibiotic available in the U.S. for this indication. The approval is supported by results from the Phase 3 PIVOT-PO trial, which demonstrated non-inferiority of oral tebipenem to intravenous imipenem-cilastatin. This new oral option is expected to reduce the strain on the healthcare system by potentially shortening hospital stays and allowing for outpatient treatment.